Oxford BioDynamics Plc

Oxford BioDynamics Plc is a biotech company focused on advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Founded in 2007 and headquartered in the United Kingdom, the company's flagship product, EpiSwitch CiRT (Checkpoint Inhibitor Response Test), is a pioneering smart blood test for cancer patients designed to guide treatment planning, assess pseudo-progression, and predict adverse events associated with immunotherapy. This innovative approach is made possible by OBD's proprietary EpiSwitch® technology, which effectively translates 3D genome regulation into clinical applications.

Oxford BioDynamics has positioned itself as a key player in the biotechnology industry through various partnerships with industry leaders and institutions such as Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. Their expertise lies in a technology portfolio spanning biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and a carefully curated 3D genome knowledgebase comprising data from thousands of samples across various human diseases. Their cutting-edge EpiSwitch technology enables the identification of abnormal genomic configurations, allowing for improved patient diagnosis and personalized treatment predictions.

In March 14, 2024, the company secured a £9.90M post-IPO equity investment. With a global presence and state-of-the-art laboratory facilities in the UK, USA, and Malaysia, Oxford BioDynamics is well-positioned to continue making significant strides in the field of personalized medicine and precision diagnostics.

For more information, please visit oxfordbiodynamics.com.